Main > ONCOLOGY (**) > Breast Cancer>HER2+>Adjuvant *** > USA. G. PertuzuMAb+TrastuzuMAb+ SC
USA. G. PertuzuMAb+TrastuzuMAb+ SC's subsections
(*) EU CE Mark Date: 2020. 12.23.
(*) USA Approval Date: 2020. 06.29
+Hyaluronidase+Docetaxel
Company
Duration: 5 Minutes
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 2
Patent>UpDate: 2021. 02.23.
TradeMark
TradeMark Web-Site
USA. G. PertuzuMAb+TrastuzuMAb+ SC's products
This section has no products